Zenith Quarterly Update
June 20, 2016

Todays Agenda for Zenith Epigenetics

- 1. Corporate Profile & Structure Review
- 2. Epigenetic Mechanism & Indication Potential
- 3. Clinical Development Plan for ZEN-3694
- 4. Market Cap Valuation & Milestones

CONTACT: Donald J. McCaffrey, Chairman, President & CEO
Suite 300, 4820 Richard Road S.W. Calgary, AB, Canada T3E 6L1
Tel: (403) 254-9252, Fax:(403) 256-8495, http://www.zenithepigenetics.com

Share Structure Profile

Founded	Corporate spin out from Resverlogix in June 2013
Status	Unlisted Possible US market IPO when conditions permit
Cash Raised 2014-2016	Approx. US$44MM @ $1.00 USD per share
Enterprise Value est.	$125 MM
Shares Outstanding	125.2 MM 134.0 MM fully diluted
Cash Burn	$2 MM per quarter - Current

2016 Current Corporate Structure

PRE JULY 31, 2016 STRUCTURE



Post July 31, 2016 Corporate Structure

POST-REORGANIZATION JULY 31, 2016 STRUCTURE



Final Corporate Structure

FUTURE FINAL RE-ORGANIZATION STRUCTURE



2. Epigenetics Mechanism and Indication Potential



Early Epigenetic Approach

Advanced Epigenetic Approach

Zenith's BRD4 Target is Directly Involved in the Resistance Mechanisms of Several Types of Anti-cancer Therapies

ZENITH EPIGENETICS

Signaling inhibitors
- γ-secretase (leukemia)
- Smoothened (medulloblastoma)
- RAF (melanoma)

Hormone-deprivation therapies
- Androgen (prostate cancer)
- Estrogen (breast cancer)



Antibody-based therapies
- Rituximab (lymphoma)



Super-enhancer cluster
BRD4

Chemotherapies
- Tamoxifen (breast cancer)
- Everolimus (breast cancer)

Cancers Escape Mechanism

Resistance mechanism involving BRD4 (treatment with BETi resensitizes cancers to these therapies)

Resistance to several standard of care treatments does not impede sensitivity to BETi

ZEN-3694 Promotes Anti-tumor Immune Responses by Targeting Multiple Checkpoints



BETi effects

BET Inhibitors Have the Potential to be Important Combination Agents With Existing Therapies



BRD4 target, is directly involved in the resistance mechanisms of several types of anti-cancer therapies

ZEN-3694 Synergizes With Several Standard of Care and Targeted Therapy Drugs in Different Cancers



Indication		Cell line (mutation)
NSCLC	▲	H1975 (EGFR L858R T790M)
	●	H820 (EGFR T790M)
	■	H2228 (ALK)
AR+ Breast	◆	MDA-MB-453
ER+ Breast	■	MCF-7 (ER+)
	▼	ZR-75-1 (ER+)
TNBC	●	HCC1937 (BRCA1)
Melanoma	✖	C32 (BRAF V600E)
	●	A375 (BRAF)
DLBCL	●	CARNAVAL (MYC/BCL2)
	●	OCI-LY18 (MYC/BCL2)
	◆	NU-DUL-1
	■	OCI-LY3 (A20)
Prostate	▼	VCAP (AR AMP/AR-V7)
AML	■	MV4-11 (MLL-AF4/FLT3-ITD)
	●	OCI-AML2 (DNMT3A/MLL)
	▼	OCI-AML3 (DNMT3A/NPM1)

ZEN-3694 Has Proven Significant Potential to Work in Patients Developing mCRPC Resistance to Enzalutamide

ZEN-3694 works down stream of current therapies

ZEN-3694 works where resistance to existing lead drugs, like enzalutamide, has evolved

The combination of ZEN-3694 & todays top medications show strong synergizes and expected reduction to resistance





Additional Resistance Pathways in CRPC in Response to Enzalutamide and/or Abiraterone

ZENITH EPIGENETICS



ZEN-3694 shows good efficacy in different CRPC models that are resistant to AR antagonists

General Information Regarding the Unmet Need in Metastatic Prostate Cancer (mCRPC)

Current Market and Unmet Need

- ~135,000 annual mCRPC patients in the US/EU alone –Majority receive enzalutamide or abiraterone as first line treatment
- **Over $4 billion in sales in 2015** for first line enzalutamide and abiraterone
- Patients are becoming resistant to these therapies, no effective second line therapy yet
- Continuing high mortality rate in resistant mCRPC (50% 1 year survival, 25% in 5 years)

Opportunity for ZEN-3694

- 2nd line single agent treatment , KOLs agree that there is no effective 2nd line treatment
  - ~60,000 2nd line treatment eligible patients in US/EU alone
- Expand into 1st line treatment in combination with enzalutamide or abiraterone

3. Clinical Development Plan for ZEN-3694



Six Leading Prostate Cancer Clinical Sites

Site	Investigators	Activation Status
UCSF	Rahul Aggarwal Eric Small	**ACTIVATED**
MSKCC	Wassim Abida Howard Scher	**ACTIVATED**
Oregon Health Sciences University	Joshi Alumkal	**ACTIVATED**
UCLA	Alan Pantuck	June/2016
Karmanos (Wayne State)	Elisabeth Heath	**ACTIVATED**
Virginia Oncology	Mark Fleming	**ACTIVATED**

- Synteract hired as Clinical Research Organization (CRO)
- Prostate Cancer Clinical Trial Consortium (PCCTC) harmonizing site activations

3 + 3 Dose Escalation Design



Note: MTD (Maximum tolerated dose) is the highest dose with ≤ 1 DLT in 6 patients. DLT is Dose Limiting Toxicity

How Can You Determine the True Potential of a New Clinical Drug Candidate in Oncology?

There are hundreds of biotech company's with potential drug candidates

Drug candidates require 3rd party Principle Investigators (PI's) to act as independent clinical investigators

The best oncology units and PI's in the United States are highly sought after

Zenith's cutting edge technology has attracted the top two U.S. PI's in prostate cancer research as well as the Prostate Cancer Clinical Trials Consortium (PCCTC)

Zenith has confirmed PI's
-Dr. Eric Small - Univ. of California, San Francisco
-Dr. Howard Scher at Memorial-Sloan Kettering , NY

Both Dr's Small & Scher where involved in the development of the top 2 current prostate drugs in use, abiraterone & enzalutamide respectively

Four of the last five FDA approved prostate drugs have come from the PCCTC which is highly selective and only champions the most promising drugs

4. Market Capitalization Valuation Rationale and Milestones

1. Oncoethix was acquired by Merck in 12/2014- $375 MM

Oncoethix only has a single BETi drug, OTX-015
Limited efficacy in Phase 1 Trials, Off target Toxicity
It is a Benzodiazepine program with poor drug like properties
$110MM payment upfront

2. Tensha was acquired by Roche in January 2016 - $535M

Sub q dosing, not orally bioavailable
Limited efficacy in Phase 1
Benzodiazepine program
$115MM payment upfront

3. Constellation received $95MM upfront in a 2012 deal

The Genentech development deal involved non-Bromodomain epigenetics with a option to buy the Bromodomain program
A phase 1 program with no published data
A Benzodiazepine program hampered by extensive cardiovascular safety in clinical monitoring

4. Market validation implied a $90MM value in 2013

On June 3rd, 2013 upon the spin out of Zenith Epigenetics from Resverlogix Corp the RVX stock adjusted by $90MM

Zenith – $125MM (est.)

- **Zenith has priced its current financing very competively compared to existing markets for less effective technologies**
- **Based on recent deal history, upcoming clinical data, and advanced biology, Zenith management expect to create additional shareholder value**

Zenith Milestone Targets

ZENITH EPIGENETICS

1 Development Targets

- ✔ Publish new Intelectual Property
- ✔ Select a new lead molecule ZEN-3694
- ✔ Select a new backup molecule – ZEN-3717
- ✔ File a 2nd IND with the FDA

2 Clinical Targets

- ✔ Top investigators recruted as leads for the program
- ✔ Initiate a clinical trial for solid tumors
- ☐ Reach proof of concept by 1H 2017
- ☐ Expand to include combination therapies

3 Corporate Development

- ☐ IPO on the Nasdaq
- ☐ Regional licensing in China and/or other countries
- ☐ Co-development partnering
- ☐ New BET Bromodomain opportunities